A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective

Rheumatology International

Volumn 36, Issue 5, 2016, Pages 685-695

  Taylor, Peter C ^a   Moore, Adam ^b,d   Vasilescu, Radu ^c   Alvir, Jose ^c   Tarallo, Miriam ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ADELPHI REAL WORLD   (United Kingdom)

^c PFIZER INC   (United States)

^d ICE Creates Ltd   (United Kingdom)

Author keywords

Cost; Fatigue; Mental functioning; Pain; Physical functioning; Rheumatoid arthritis

Indexed keywords

DISEASE DURATION; DISEASE SEVERITY; FATIGUE; FUNCTIONAL STATUS; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE NEED; HUMAN; MENTAL FUNCTION; PAIN; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SEXUALITY; SOCIAL INTERACTION; SYSTEMATIC REVIEW; ARTHRITIS, RHEUMATOID; COMPLICATION; COST OF ILLNESS; HEALTH SERVICE;

ARTHRITIS, RHEUMATOID; COST OF ILLNESS; FATIGUE; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; PAIN; QUALITY OF LIFE;

EID: 84953380615     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3415-x     Document Type: Review

References (79)

1. World Health Organization Chronic rheumatic conditions. http://www.who.int/chp/topics/rheumatic/en/. Accessed 13 Oct 2014
2. Englbrecht M, Kruckow M, Araujo E, Rech J, Schett G (2013) The interaction of physical function and emotional well-being in rheumatoid arthritis—what is the impact on disease activity and coping? Semin Arthritis Rheum 42:482–491. doi:10.1016/j.semarthrit.2012.09.003
3. Aggarwal A, Chandran S, Misra R (2006) Physical, psychosocial and economic impact of rheumatoid arthritis: a pilot study of patients seen at a tertiary care referral centre. Natl Med J India 19:187–191
4. Mittendorf T, Dietz B, Sterz R, Cifaldi MA, Kupper H, von der Schulenburg JM (2008) Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient’s perspective. Rheumatology 47:188–193. doi:10.1093/rheumatology/kem317
5. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509. doi:10.1136/annrheumdis-2013-204573
6. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784. doi:10.1002/art.23721
7. Taylor PC (2010) The importance of the patients’ experience of RA compared with clinical measures of disease activity. Clin Exp Rheumatol 28:S28–S31
8. Keystone EC, Smolen J, van Riel P (2012) Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology 51(Suppl 5):v48–v54. doi:10.1093/rheumatology/kes122
9. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, Kirwan J (2003) Rheumatology outcomes: the patient’s perspective. J Rheumatol 30:880–883
10. Sokka T (2011) Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice. Scand J Rheumatol Suppl 125:23–27. doi:10.3109/03009742.2011.566437
11. Fleischmann R (2009) The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life. Open Access Rheumatol Res Rev 1:95–106
12. Gronning K, Rodevand E, Steinsbekk A (2010) Paid work is associated with improved health-related quality of life in patients with rheumatoid arthritis. Clin Rheumatol 29:1317–1322. doi:10.1007/s10067-010-1534-z
13. Sarzi-Puttini P, Fiorini T, Panni B, Turiel M, Cazzola M, Atzeni F (2002) Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. BMC Musculoskelet Disord 3:18
14. Lempp H, Hofmann D, Hatch SL, Scott DL (2012) Patients’ views about treatment with combination therapy for rheumatoid arthritis: a comparative qualitative study. BMC Musculoskelet Disord 13:200
15. Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y (2006) Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology 45:1238–1246. doi:10.1093/rheumatology/kel066
16. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA (1993) Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol 20:557–560
17. Strand V, Singh JA (2010) Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 70:121–145. doi:10.2165/11531980-000000000-00000
18. Stockl KM, Shin JS, Lew HC, Zakharyan A, Harada AS, Solow BK, Curtis BS (2010) Outcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherence. J Manag Care Pharm 16:593–604
19. Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N (2006) Community-based evaluation of etanercept in patients with rheumatoid arthritis. J Rheumatol 33:665–670
20. Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, Vlahos B, Pedersen R, Singh A (2013) Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord 14:13. doi:10.1186/1471-2474-14-13
21. Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, Fabo T, Bananis E, Jones H, Szumski A, Tang B, Kotak S, Koenig AS, Vasilescu R (2013) Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clin Rheumatol 32:1275–1281. doi:10.1007/s10067-013-2240-4
22. Hodkinson B, Musenge E, Ally M, Meyer PW, Anderson R, Tikly M (2012) Functional disability and health-related quality of life in South Africans with early rheumatoid arthritis. Scand J Rheumatol 41:366–374. doi:10.3109/03009742.2012.676065
23. Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, Magilavy DB (2013) Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol 40:369–378. doi:10.3899/jrheum.120923
24. Ibn Yacoub Y, Amine B, Laatiris A, Wafki F, Znat F, Hajjaj-Hassouni N (2012) Fatigue and severity of rheumatoid arthritis in Moroccan patients. Rheumatol Int 32:1901–1907. doi:10.1007/s00296-011-1876-0
25. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA (2004) Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 51:578–585. doi:10.1002/art.20539
26. Tack BB (1990) Self-reported fatigue in rheumatoid arthritis: a pilot study. Arthritis Care Res 3:154–157
27. Wolfe F, Hawley DJ, Wilson K (1996) The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 23:1407–1417
28. Pinals RS, Masi AT, Larsen RA (1981) Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 24:1308–1315
29. Ahlmen M, Nordenskiold U, Archenholtz B, Thyberg I, Ronnqvist R, Linden L, Andersson AK, Mannerkorpi K (2005) Rheumatology outcomes: the patient’s perspective. A multicentre focus group interview study of Swedish rheumatoid arthritis patients. Rheumatology 44:105–110. doi:10.1093/rheumatology/keh412
30. Belza BL (1995) Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 22:639–643
31. McInnes IB, Combe B, Burmester G (2013) Understanding the patient perspective—results of the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) patient needs survey. Clin Exp Rheumatol 31:350–357
32. da Mota LM, Dos Santos Neto LL, Oliveira AC, Pereira IA, Burlingame RW, Menard HA, Laurindo IM (2012) Baseline HAQ and SF-36 questionnaire scores cannot predict clinical remission, radiographic progression or the need for biological therapy in a three-year prospective study of a Brazilian early rheumatoid arthritis cohort. Rheumatol Int 32:3937–3943. doi:10.1007/s00296-011-2261-8
33. Abdel-Nasser AM, Ali EI (2006) Determinants of sexual disability and dissatisfaction in female patients with rheumatoid arthritis. Clin Rheumatol 25:822–830
34. El Miedany Y, El Gaafary M, El Aroussy N, Youssef S, Ahmed I (2012) Sexual dysfunction in rheumatoid arthritis patients: arthritis and beyond. Clin Rheumatol 31:601–606. doi:10.1007/s10067-011-1891-2
35. Marshall NJ, Wilson G, Lapworth K, Kay LJ (2004) Patients’ perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology 43:1034–1038. doi:10.1093/rheumatology/keh237
36. Striesow F, Brandt A (2012) Preference, satisfaction and usability of subcutaneously administered methotrexate for rheumatoid arthritis or psoriatic arthritis: results of a postmarketing surveillance study with a high-concentration formulation. Ther Adv Musculoskelet Dis 4:3–9. doi:10.1177/1759720X11431004
37. Scott DL, Smith C, Kingsley G (2005) What are the consequences of early rheumatoid arthritis for the individual? Best Pract Res Clin Rheumatol 19:117–136. doi:10.1016/j.berh.2004.08.007
38. Young A, Dixey J, Kulinskaya E, Cox N, Davies P, Devlin J, Emery P, Gough A, James D, Prouse P, Williams P, Winfield J (2002) Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 61:335–340
39. Albers JM, Kuper HH, van Riel PL, Prevoo ML, van ‘t Hof MA, van Gestel AM, Severens JL (1999) Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology 38:423–430
40. Young A, Dixey J, Cox N, Davies P, Devlin J, Emery P, Gallivan S, Gough A, James D, Prouse P, Williams P, Winfield J (2000) How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology 39:603–611
41. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Hakala M, Korpela M, Ilva K, Yli-Kerttula U, Piirainen H, Leirisalo-Repo M (2005) Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis 64:130–133. doi:10.1136/ard.2003.019034
42. Burton W, Morrison A, Maclean R, Ruderman E (2006) Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 56:18–27. doi:10.1093/occmed/kqi171
43. Furuya H, Kasama T, Isozaki T, Umemura M, Otsuka K, Isojima S, Tsukamoto H, Tokunaga T, Yanai R, Takahashi R (2013) Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis. J Multidiscip Healthc 6:25–30
44. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blafield H, Hakala M, Leirisalo-Repo M (2004) Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 50:55–62. doi:10.1002/art.11436
45. Lundkvist J, Kastäng F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8(Suppl 2):S49–S60
46. Kavanaugh A (2007) Economic consequences of established rheumatoid arthritis and its treatment. Best Pract Res Clin Rheumatol 21:929–942. doi:10.1016/j.berh.2007.05.005
47. McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA (2011) Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid arthritis. J Rheumatol 38:2141–2149
48. Jönsson B, Kobelt G, Smolen J The burden of rheumatoid arthritis (RA) and patient access to treatment: summary of key findings. https://www.medscinet.com/Ehe/TB_images/RA_Brochure.pdf. Accessed 11 Jan 2015
49. Berkanovic E, Hurwicz ML, Lachenbruch PA (1995) Concordant and discrepant views of patients’ physical functioning. Arthritis Care Res 8:94–101
50. Hewlett S, Smith AP, Kirwan JR (2001) Values for function in rheumatoid arthritis: patients, professionals, and public. Ann Rheum Dis 60:928–933
51. Kvien TK, Heiberg T (2003) Patient perspective in outcome assessments–perceptions or something more? J Rheumatol 30:873–876
52. de Wit MP, Smolen JS, Gossec L, van der Heijde DM (2011) Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 70:891–895. doi:10.1136/ard.2010.146662
53. Coenen M, Cieza A, Stamm TA, Amann E, Kollerits B, Stucki G (2006) Validation of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis from the patient perspective using focus groups. Arthritis Res Ther 8:R84. doi:10.1186/ar1956
54. Lesko M, Young M, Higham R (2010) Managing inflammatory arthritides: role of the nurse practitioner and physician assistant. J Am Acad Nurse Pract 22:382–392. doi:10.1111/j.1745-7599.2010.00525.x
55. Rheumatoid Patient Foundation (2013) Unmasking rheumatoid disease: the patient experience of rheumatoid arthritis. http://rheum4us.org/wp-content/uploads/2013/04/Unmasking-Rheumatoid-Disease-The-Patient-Experience-of-Rheumatoid-Arthritis-White-Paper.pdf. Accessed 9 Mar 2015
56. Strand V, Singh JA (2008) Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 14:234–254
57. Pope JE, Khanna D, Norrie D, Ouimet JM (2009) The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. J Rheumatol 36:254–259. doi:10.3899/jrheum.080479
58. Wells G, Li T, Maxwell L, MacLean R, Tugwell P (2007) Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 34:280–289
59. Hallert E, Bjork M, Dahlstrom O, Skogh T, Thyberg I (2012) Disease activity and disability in women and men with early rheumatoid arthritis (RA): an 8-year followup of a Swedish early RA project. Arthritis Care Res 64:1101–1107. doi:10.1002/acr.21662
60. Katz P, Yelin E, Patel V, Huang XY, Chiou CF (2009) Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists. Arthritis Rheum 61:593–599. doi:10.1002/art.24511
61. Soderlin MK, Lindroth Y, Jacobsson LT (2007) Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. Rheumatology 46:1355–1358. doi:10.1093/rheumatology/kem143
62. Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF (2010) Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). Ann Rheum Dis 69:126–131. doi:10.1136/ard.2009.108035
63. Soderlin MK, Lindroth Y, Turesson C, Jacobsson LT (2010) A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmo, Sweden, 1997–2005. Scand J Rheumatol 39:206–211. doi:10.3109/03009740903313621
64. Sokka T, Kautiainen H, Pincus T, Verstappen SM, Aggarwal A, Alten R, Andersone D, Badsha H, Baecklund E, Belmonte M, Craig-Muller J, da Mota LM, Dimic A, Fathi NA, Ferraccioli G, Fukuda W, Geher P, Gogus F, Hajjaj-Hassouni N, Hamoud H, Haugeberg G, Henrohn D, Horslev-Petersen K, Ionescu R, Karateew D, Kuuse R, Laurindo IM, Lazovskis J, Luukkainen R, Mofti A, Murphy E, Nakajima A, Oyoo O, Pandya SC, Pohl C, Predeteanu D, Rexhepi M, Rexhepi S, Sharma B, Shono E, Sibilia J, Sierakowski S, Skopouli FN, Stropuviene S, Toloza S, Valter I, Woolf A, Yamanaka H (2010) Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 12:R42. doi:10.1186/ar2951
65. Uhlig T, Heiberg T, Mowinckel P, Kvien TK (2008) Rheumatoid arthritis is milder in the new millennium: health status in patients with rheumatoid arthritis 1994–2004. Ann Rheum Dis 67:1710–1715. doi:10.1136/ard.2007.084673
66. Wolfe F, Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choices. Arthritis Rheum 56:2135–2142. doi:10.1002/art.22719
67. Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC (2009) Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 27:907–913
68. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, Lencina V, Scolnik M, Waimann C, Navarta D, Citera G, Soriano ER (2013) Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health 16:385–393. doi:10.1016/j.jval.2012.11.007
69. Kovalchik SA, Charles-Schoeman C, Khanna D, Paulus HE (2012) An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. Rheumatol Int 32:2725–2729. doi:10.1007/s00296-011-2037-1
70. Pfeiffer BM, Krenzer S, Dockhorn R, Schwenke R, Schwenke H, Waehrisch J, Kraus E (2013) Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis. Rheumatol Int 33:1447–1454. doi:10.1007/s00296-012-2583-1
71. Staples MP, March L, Lassere M, Reid C, Buchbinder R (2011) Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database. Rheumatology 50:166–175. doi:10.1093/rheumatology/keq322
72. Uutela T, Hannonen P, Kautiainen H, Hakala M, Hakkinen A (2011) Sustained improvement of health-related quality of life in patients with early rheumatoid arthritis: a ten-year follow-up study. Clin Exp Rheumatol 29:65–71
73. Yalçin T, Bal A, Dülgeroğlu D, Çakci A (2012) Follow-up results of our patients with rheumatoid arthritis. Turk J Rheumatol 27:98–108
74. Campbell RC, Batley M, Hammond A, Ibrahim F, Kingsley G, Scott DL (2012) The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clin Rheumatol 31:717–722. doi:10.1007/s10067-011-1887-y
75. van Os S, Norton S, Hughes LD, Chilcot J (2012) Illness perceptions account for variation in positive outlook as well as psychological distress in rheumatoid arthritis. Psychol Health Med 17:427–439. doi:10.1080/13548506.2011.626432
76. Ibn Yacoub Y, Amine B, Laatiris A, Hajjaj-Hassouni N (2012) Health-related quality of life in Moroccan patients with rheumatoid arthritis. Clin Rheumatol 31:1471–1477. doi:10.1007/s10067-012-2037-x
77. Wallenius M, Skomsvoll JF, Koldingsnes W, Rodevand E, Mikkelsen K, Kaufmann C, Kvien TK (2009) Comparison of work disability and health-related quality of life between males and females with rheumatoid arthritis below the age of 45 years. Scand J Rheumatol 38:178–183. doi:10.1080/03009740802400594
78. Pietrapertosa D, Salaffi F, Peluso G, Bosello SL, Fedele AL, Cuoghi I, Michelutti A, Gremese E, Ferraccioli GF (2009) Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome. Rheumatology 48:1242–1246. doi:10.1093/rheumatology/kep217
79. Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB (2008) Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis 67(7):967–971